IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: CRESPO CRESPO, Confirmation No.: 6572

Maria, et al.

Serial No.: 10/582,704 Group Art Unit: 1624

Filed: June 1, 2007 Examiner: Deepak R. RAO

FOR: 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR

ANTAGONISTS

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §\$1.97 and 1.98.

\boxtimes	Pursuant to 37 C.F.R. §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed.
	No copies of the publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.
	No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98.
	Publication WO 2005/047279, listed on the attached Form PTO/SB/08 was cited in an examination report issued in connection with Japanese Patent Application 2006-545817 (corresponding to U.S. Application No. 10/582,704), and mailed on November 9, 2010.

Attorney Docket No. LABO-003/02US 311815-2022 Serial No. 10/582,704

		·			
		§609 of the M.P.E.P., Applicant su	sh publication(s) Pursuant ubmits the attached foreign search a non-English language publication(s)	or	
		Enclosed is a copy of a non-Enclosed is a copy of a non-English publication.	nglish publication(s) English nclosed) claims priority from this not		
		Enclosed is an explanation of non-E an English translation is not availabl	English publication(s) for whice.	ch	
			ion of non-English publication lovember 9, 2010, cited in the attached		
		Enclosed is a copy of pending patent	t Application Serial No		
C.F.R.	This Information Disclosure Statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing of any of the following:				
		a final action under 37 C.F.R	., §1.113;		
		a notice of allowance under 3	37 C.F.R. §1.311; or		
		an action that otherwise close	es prosecution in this application.		
	In accordance with 37 C.F.R. §1.97(c) also enclosed is:				
		Fee under 37 C.F.R. §1.17(p)) in the amount of \$180.00; <u>or</u>		
		Statement as specified in 37	C.F.R. §1.97(e):		
		Disclosure Statemen communication from counterpart foreign a	mation contained in the Information to cited herein was first cited in m a foreign patent office in pplication not more than three mont date of the Information Disclosure.	a a hs	
		· · · · · · · · · · · · · · · · · · ·			
		Disclosure Statemen communication from	nation contained in the Information t submitted herewith was cited in man a foreign patent office in	a a	
		the undersigned, havi of information cont Statement was know C.F.R. §1.56(c) more	application, and, to the knowledge ing made a reasonable inquiry, no ite ained in the Information Disclosu on to any individual designated in the e than three months prior to the filition Disclosure Statement.	em ire 37	

Attorney Docket No. LABO-003/02US 311815-2022 Serial No. 10/582,704

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

Dated: January 6, 2011

Respectfully submitted, **COOLEY LLP**

COOLEY LLP ATTN: Patent Group 777 6th Street NW, Suite 1100 Washington, DC 20001

Tel: (212) 479-6821 Fax: (202) 842-7899 By:

Joshua S. Marcus, Ph.D. Reg. No. 60,968